AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 271 min read$JAZZ

McSharry Heather Ann sold $482K of JAZZ

McSharry Heather Ann sold 2,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $241.00 ($0.48M total) on 2026-05-22.

Original reporting
SEC EDGAR · McSharry Heather Ann
Published May 27, 2026, 10:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$JAZZ
Neutral
medium confidence
Mentioned
$JAZZ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JAZZNeutralLow
01

Why it matters

Treat as a sentiment/positioning datapoint rather than a fundamental catalyst; monitor for subsequent insider buys/sales or earnings/guidance changes.

02

Market read

A single director sale (~$482k) may slightly weigh on sentiment, but without corroborating company news the trading impact should be muted.

03

What to watch

No 10b5-1 plan is cited; however, Form 4s often reflect non-informational motives, and the article provides no context on prior buying/selling patterns.

Relevance 6/10Timing: Immediate (today’s filing) but expected to have limited follow-through absent additional catalysts.

Background

SEC Form 4 reports insider transactions; this filing documents a director’s open-market sale of Jazz Pharmaceuticals shares.

Company-level read

Ticker impact

$JAZZNeutralMedium confidence
Context

Jazz Pharmaceuticals director Heather Ann McSharry filed an open-market sale of 2,000 shares at $241/share for ~$482k, disclosed via SEC Form 4.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless follow-on disclosures or fundamentals change.

Evidence & confidence

The filing is a routine director sale (no 10b5-1 plan stated) with modest size relative to typical liquidity; without accompanying company news, directional inference is weak.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector/regulatory catalyst.

Regional

None indicated; disclosure is US SEC EDGAR and does not reference regional operations.

Global

None indicated; no international deal/regulatory event mentioned.

Counterpoint

What could challenge this read

The sale may reflect diversification, tax planning, or scheduled liquidity needs rather than a negative view on Jazz fundamentals.

Key entities

  • issuer
    Jazz Pharmaceuticals plc

    Subject of the SEC Form 4 insider transaction disclosure.

  • director
    Heather Ann McSharry

    Director who sold 2,000 shares in an open-market transaction.

Read at source← All news

Related articles

AUG 7
$JAZZMed

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

Jazz Pharmaceuticals said it will seek FDA removal of the second-line indication for lurbinectedin (Zepzelca) in metastatic small-cell lung cancer. Jazz plans a labeling supplement submission in Q3 2026. The indication was accelerated in 2020. The phase 3 LAGOON trial failed its overall survival endpoint, with median OS 8.7 vs 10.7 months (HR 1.19) for monotherapy. First-line maintenance remains unchanged.

medscape.com3 min
AUG 3
$JAZZHighAI 9/10

Jazz Pharmaceuticals plc (JAZZ): Results of Operations and Financial Condition

Jazz Pharmaceuticals plc (JAZZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26financialpr.htm EX-99.1 Document Exhibit 99.1 Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results – Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company raises 2026 revenue guidance – – Prepared to laun

SEC EDGAR 8-K6 min
JUL 25
$JAZZMed

WestJet and Jazz Face August Strike Deadlines That Could Ground Your Long Weekend Flight

WestJet says it will allow one free change or cancellation for bookings departing July 30 to Aug 4, covering WestJet mainline flights only. CUPE Local 8125, representing WestJet cabin crew, can legally strike from Aug 2 after a 21-day cooling-off period. Jazz dispatchers can legally strike from Aug 1, potentially disrupting Air Canada Express flights. Air Canada mainline is not directly at strike risk.

travelerstoday.com7 min
JUL 14
$JAZZMedAI 8/10

Jazz completes acquisition of TPL Insurance, secures 76.33% stake

Jazz International Holding completed its acquisition of TPL Insurance, taking control after buying a 76.33% stake. TPL Insurance said the deal was finalized July 13, 2026, under a share purchase agreement with TPL Corp and a mandatory tender offer. The controlling stake sale was valued at about Rs4.15 billion, with SECP and CCP approvals in Feb and Apr 2026.

pakobserver.net4 min